YUSRA MEDIK

Dr. YUSRA MEDIK


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
YMYUSRA MEDIK
YUSRA MEDIK
SSSehrish Sardar
Sehrish Sardar
JSJaskirat S. Sethi
Jaskirat S. Sethi
MBMarcelo P. Bigarella
Marcelo P. Bigarella
SSSunny R. K. Singh
Sunny R. K. Singh
Shi-Ming TuShi-Ming Tu
Shi-Ming Tu
In this Perspective, we discuss a stem cell origin of cancer and consider the biological principles and clinical strategies for chemoprevention in cancer care. We examine the role of vitamin D, tumor microenvironment, and GLP-1R agonists in chemoprevention and maintenance therapy. If cancer were a stem cell disease, then keeping stem cells pristine and healthy would be essential and keeping cancer stem cells (CSC) dormant and innocuous necessary. According to a stem cell (unified) theory of cancer, chemoprevention is effective when we refrain from disturbing CSCs and/or inciting non-CSCs with inflammatory factors and/or insulinemic habits. We postulate that many effective chemoprevention (and anti-cancer) treatments modulate stem-ness/stem-like cells and operate through anti-stem-ness/stem-like mechanisms. They affect progenitor stem cells versus progeny differentiated cells as well as their malignant counterparts and respective microenvironments. We propose that to fulfill the visions and missions of cancer prevention, it is imperative to first formulate a pertinent scientific theory and then adopt and adhere to the proper scientific method in our conduct of cancer research and provision of cancer care.

20 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
TSTrilok Shrivastava
Trilok Shrivastava
YMYUSRA MEDIK
YUSRA MEDIK
NKNikhila Sampath Kumar
Nikhila Sampath Kumar
Shi-Ming TuShi-Ming Tu
Shi-Ming Tu
AKAnuradha Kunthur
Anuradha Kunthur
Background/Objectives: Non-clear cell renal cell carcinoma (nccRCC) comprises biologically heterogeneous renal malignancies with distinct molecular drivers, clinical behavior, and therapeutic responses. This review summarizes prognosis and systemic therapy and evaluates emerging histology-specific and biomarker-directed approaches. Methods: We analyzed overall survival by histology in the SEER 17 Registries database (2000–2022) and conducted a narrative review of trials, guidelines, and translational studies. The ICD-O-3-defined population included 43,966 adults; 43,789 with known survival time were included in survival analyses. Results: Median follow-up was 96 months. Compared with papillary RCC, adjusted HRs were 0.67 (95% CI 0.64–0.70) for chromophobe RCC, 3.73 (3.37–4.11) for collecting duct carcinoma, 0.97 (0.80–1.17) for oncocytic tumors, and 33.23 (27.47–40.20) for medullary carcinoma. VEGFR- and MET-directed therapies and immune checkpoint inhibitor combinations show activity that varies by histology. Conclusions: nccRCC should be studied and managed as a collection of distinct entities. Registry associations require cautious interpretation because of residual confounding, evolving classification, and non-proportional hazards; subtype-specific trials and molecular stratification remain priorities.

7 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
TSTrilok Shrivastava
Trilok Shrivastava
YMYUSRA MEDIK
YUSRA MEDIK
NKNikhila Sampath Kumar
Nikhila Sampath Kumar
Shi-Ming TuShi-Ming Tu
Shi-Ming Tu
AKAnuradha Kunthur
Anuradha Kunthur
Background/Objectives: Non-clear cell renal cell carcinoma (nccRCC) comprises biologically heterogeneous renal malignancies with distinct molecular drivers, clinical behavior, and therapeutic responses. This review summarizes prognosis and systemic therapy and evaluates emerging histology-specific and biomarker-directed approaches. Methods: We analyzed overall survival by histology in the SEER 17 Registries database (2000–2022) and conducted a narrative review of trials, guidelines, and translational studies. The ICD-O-3-defined population included 43,966 adults; 43,789 with known survival time were included in survival analyses. Results: Median follow-up was 96 months. Compared with papillary RCC, adjusted HRs were 0.67 (95% CI 0.64–0.70) for chromophobe RCC, 3.73 (3.37–4.11) for collecting duct carcinoma, 0.97 (0.80–1.17) for oncocytic tumors, and 33.23 (27.47–40.20) for medullary carcinoma. VEGFR- and MET-directed therapies and immune checkpoint inhibitor combinations show activity that varies by histology. Conclusions: nccRCC should be studied and managed as a collection of distinct entities. Registry associations require cautious interpretation because of residual confounding, evolving classification, and non-proportional hazards; subtype-specific trials and molecular stratification remain priorities.